Press Enter to search · ESC to close

Macro

China NMPA Accepts Novo Nordisk’s CagriSema Weight-Loss Drug Application

Novo Nordisk said China’s National Medical Products Administration has accepted its marketing application for CagriSema (cagrilintide and semaglutide injection) for long-term weight management. The fixed-dose combination pairs a long-acting amylin receptor agonist with the GLP-1 receptor agonist semaglutide and is given as a once-weekly subcutaneous injection. The two components act through distinct, complementary mechanisms on appetite and body-weight regulation pathways.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback